1. Home
  2. IHG vs GMAB Comparison

IHG vs GMAB Comparison

Compare IHG & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IHG
  • GMAB
  • Stock Information
  • Founded
  • IHG 1777
  • GMAB 1999
  • Country
  • IHG United Kingdom
  • GMAB Denmark
  • Employees
  • IHG N/A
  • GMAB N/A
  • Industry
  • IHG Hotels/Resorts
  • GMAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • IHG Consumer Discretionary
  • GMAB Health Care
  • Exchange
  • IHG Nasdaq
  • GMAB Nasdaq
  • Market Cap
  • IHG 17.0B
  • GMAB 15.4B
  • IPO Year
  • IHG N/A
  • GMAB N/A
  • Fundamental
  • Price
  • IHG $122.25
  • GMAB $28.35
  • Analyst Decision
  • IHG Sell
  • GMAB Buy
  • Analyst Count
  • IHG 2
  • GMAB 6
  • Target Price
  • IHG N/A
  • GMAB $37.60
  • AVG Volume (30 Days)
  • IHG 174.8K
  • GMAB 1.4M
  • Earning Date
  • IHG 01-01-0001
  • GMAB 11-05-2025
  • Dividend Yield
  • IHG 1.36%
  • GMAB N/A
  • EPS Growth
  • IHG 21.99
  • GMAB 77.72
  • EPS
  • IHG 4.70
  • GMAB 21.62
  • Revenue
  • IHG $5,120,000,000.00
  • GMAB $3,646,881,232.00
  • Revenue This Year
  • IHG N/A
  • GMAB $22.68
  • Revenue Next Year
  • IHG $6.19
  • GMAB $15.85
  • P/E Ratio
  • IHG $26.23
  • GMAB $1.32
  • Revenue Growth
  • IHG 33.89
  • GMAB 32.97
  • 52 Week Low
  • IHG $94.78
  • GMAB $17.24
  • 52 Week High
  • IHG $137.25
  • GMAB $28.74
  • Technical
  • Relative Strength Index (RSI)
  • IHG 52.42
  • GMAB 77.61
  • Support Level
  • IHG $121.74
  • GMAB $27.58
  • Resistance Level
  • IHG $125.32
  • GMAB $28.75
  • Average True Range (ATR)
  • IHG 1.41
  • GMAB 0.36
  • MACD
  • IHG -0.06
  • GMAB 0.23
  • Stochastic Oscillator
  • IHG 52.11
  • GMAB 91.15

About IHG Intercontinental Hotels Group

InterContinental Hotels Group operates 987,000 rooms across 19 brands addressing the midscale through luxury segments, as of Dec. 31, 2024. Holiday Inn and Holiday Inn Express constitute the largest brand, while Hotel Indigo, Even, Hualuxe, Kimpton, and Voco are newer lifestyle brands experiencing strong demand. The company launched a midscale brand, Avid, in 2017 and closed on a 51% stake in Regent Hotels in 2018. It acquired Six Senses in 2019 and launched another midscale brand, Garner, in 2023. Managed and franchised represent 99% of total rooms. As of Dec. 31, 2024, the Americas represented 53% of total rooms, with Greater China accounting for 20% and Europe, Asia, the Middle East, and Africa making up 27%.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: